Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413751 · ClinicalTrials.gov registry record
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
A clinical trial, sponsored by Walter Reed Army Medical Center.
- Completed
- Registry status
- 20
- Enrollment target
NCT00413751: Completed study, sponsored by Walter Reed Army Medical Center.
NCT00413751 is a clinical trial that has completed, run by Walter Reed Army Medical Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413751 has completed, sponsored by Walter Reed Army Medical Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Interventions
- DRUG Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
What the finished NCT00413751 record still lists
NCT00413751 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) is the first listed.
NCT00413751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00413751 about?
NCT00413751 is a clinical study titled "Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes". The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
What is the current status of trial NCT00413751?
This trial is currently completed. The enrollment target is 20 participants.
What interventions are being tested in trial NCT00413751?
The interventions under investigation include: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) (DRUG).
Who is sponsoring clinical trial NCT00413751?
This trial is sponsored by Walter Reed Army Medical Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)